These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making. The gene discussed is ATM; the disease is B-cell chronic lymphocytic leukemia.